Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.51 |
| ▸ | BRAF | P15056 | 12/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27305737 | 0.92 | KDR (0.54) | KDRBRAFMAPK14MAPK13 | |
| SCHEMBL30729917 | 0.84 | KDR (0.70) | KDRBRAF | |
| SCHEMBL15541508 | 0.84 | KDR (0.70) | KDRBRAF | |
| SCHEMBL30729916 | 0.84 | KDR (0.70) | KDRBRAF | |
| SCHEMBL27311398 | 0.82 | KDR (0.66) | KDRBRAF | |
| SCHEMBL24037399 | 0.80 | MAPK13 (0.49) | KDRBRAFMAPK14MAPK13 | |
| SCHEMBL16895218 | 0.78 | MAPK14 (0.53) | KDRBRAFMAPK14MAPK13 | |
| SCHEMBL27300481 | 0.78 | TGFBR1 (0.46) | KDRBRAFMAPK14 | |
| SCHEMBL30729902 | 0.78 | MAPK14 (0.53) | KDRBRAFMAPK14MAPK13 | |
| SCHEMBL27096971 | 0.78 | MAPK14 (0.52) | KDRBRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2022170043-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ERBB2, EGFR, ERBB4 | KDR 48/4885BRAF 16/4885MAPK14 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.